FDA Requires Long-Track Approval for Collplant’s Wound Dressing

CollPlant Holdings announced that the FDA is requiring the long-track premarket approval, rather than the fast-track 510(k) approval process for the company’s Vergenex wound dressing matrix for chronic wounds.
Globes